CHF6001

Research use only, not for human use.

A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM.

A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM; inhibits PDE4 isoforms A-D with equal potency, 7- and 923-fold more potent than roflumilast and cilomilast, and displays >20,000-fold selectivity versus PDE4 compared with a panel of PDEs; effectively inhibits (subnanomolar IC50 values) the release of TNF-α from human PBMCs, THP-1, and rodent macrophages; inhibitsLPS-induced pulmonary neutrophilia (ED50=0.205 uM/kg) and leukocyte infiltration (ED50=0.188 uM/kg) in rats.COPD Phase 2 Clinical

CHF-6001;CHF 6001

Angiogenesis

PDE

PDE

Inflammation/Immunology

COPD

1239278-59-1

687.53

C30H30Cl2F2N2O8S

>98% (HPLC)

——

O=C(O[C@H](C1=CC=C(OC(F)F)C(OCC2CC2)=C1)CC3=C(Cl)C=[N+]([O-])C=C3Cl)C4=CC=C(NS(=O)(C)=O)C(OCC5CC5)=C4

(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide

(-20℃)

With Ice Pack

≥ 2 years